Education
About Us
Working with TipRanks
Follow Us
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
BDRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.78 - $17.88
Previous CloseN/A
Volume6.04K
Average Volume (3M)2.89M
Market Cap
$588.36K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Sep 11, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding5,050,631
10 Day Avg. Volume2,484,607
30 Day Avg. Volume2,885,106
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside1993.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $0.78 and its highest was $17.88 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $588.36K.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
Biodexa Pharmaceuticals’s upcoming earnings report date is Sep 11, 2025 which is in 43 days.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Biodexa Pharmaceuticals released its earnings results on Apr 11, 2025. The company reported -$0.001 earnings per share for the quarter, the consensus estimate of -$0.001 by $0.
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Undervalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate is 0.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 5,050,631 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Biodexa Pharmaceuticals reported an EPS of -$0.001 in its last earnings report, expectations of -$0.001. Following the earnings report the stock price went up 12.739%.
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Technical Analysis
Kazia Therapeutics
―
Oragenics
―
Xenetic Biosciences
―
NLS Pharmaceutics
―
Pasithea Therapeutics Corp
―
Ownership Overview
1.87%
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
98.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---